Human immunodeficiency virus protease inhibitors

被引:26
|
作者
Rana, KZ
Dudley, MN
机构
[1] Univ Rhode Isl, Coll Pharm, Roger Williams Med Ctr, Antiinfect Pharmacol Res Unit, Providence, RI 02908 USA
[2] Microcide Pharmaceut, Mountain View, CA USA
来源
PHARMACOTHERAPY | 1999年 / 19卷 / 01期
关键词
D O I
10.1592/phco.19.1.35.30513
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Human immunodeficiency virus (HIV) protease inhibitors have revolutionized the treatment of individuals infected with this pathogen. The protease is an enzyme that is essential for viral replication because it cleaves both structural and functional proteins from precursor viral polyprotein strands. Inhibition of this process suppresses viral replication, which produces immature noninfectious virions. When combined with reverse transcriptase inhibitors, these agents are very potent in suppressing viral replication. Pharmacologic properties, toxic profile, drug interactions, and resistance patterns differ among protease inhibitors, and all must be considered when selecting the drugs for therapeutic use in humans. The best combination, sequence of use, durability of response, and magnitude of immune reconstitution and function are issues that have yet to be fully elucidated.
引用
收藏
页码:35 / 59
页数:25
相关论文
共 50 条
  • [31] In vitro activity of human immunodeficiency virus protease inhibitors against Pneumocystis carinii
    Atzori, C
    Angeli, E
    Mainini, A
    Agostoni, F
    Micheli, V
    Cargnel, A
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (05): : 1629 - 1634
  • [32] MULTIPLE MUTATIONS IN THE HUMAN-IMMUNODEFICIENCY-VIRUS PROTEASE GENE ARE RESPONSIBLE FOR DECREASED SUSCEPTIBILITY TO PROTEASE INHIBITORS
    KING, RW
    GARBER, S
    WINSLOW, DL
    REID, C
    BACHELER, LT
    ANTON, E
    OTTO, MJ
    [J]. ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1995, 6 (02): : 80 - 88
  • [33] Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors
    Svicher, V
    Ceccherini-Silberstein, F
    Erba, F
    Santoro, M
    Gori, C
    Bellocchi, MC
    Giannella, S
    Trotta, MP
    Monforte, AD
    Antinori, A
    Pern, CF
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (05) : 2015 - 2025
  • [34] Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines
    Vernochet, C
    Azoulay, S
    Duval, D
    Guedj, R
    Cottrez, F
    Vidal, H
    Ailhaud, G
    Dani, C
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (03) : 2238 - 2243
  • [35] Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors
    Doyon, L
    Croteau, G
    Thibeault, D
    Poulin, F
    Pilote, L
    Lamarre, D
    [J]. JOURNAL OF VIROLOGY, 1996, 70 (06) : 3763 - 3769
  • [36] The effect of human immunodeficiency virus-1 protease inhibitors on the toxicity of a variety of cells
    Germinario, RJ
    Colby-Germinario, SP
    [J]. IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL, 2003, 39 (07) : 275 - 279
  • [37] NON-PEPTIDE-BASED INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS-1 PROTEASE
    PEYMAN, A
    STAHL, W
    WAGNER, K
    RUPPERT, D
    BUDT, KH
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1994, 4 (21) : 2601 - 2604
  • [38] Use of human immunodeficiency virus-1 protease inhibitors is associated with endothelial dysfunction
    Klein, MA
    Sosman, JM
    Bellehumeur, JL
    Aeschlimann, SE
    Stein, JH
    [J]. CIRCULATION, 1999, 100 (18) : 146 - 146
  • [39] DESIGN OF SYMMETRY-BASED, PEPTIDOMIMETIC INHIBITORS OF HUMAN-IMMUNODEFICIENCY-VIRUS PROTEASE
    KEMPF, DJ
    [J]. RETROVIRAL PROTEASES, 1994, 241 : 334 - 354
  • [40] Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis
    Narita, M
    Stambaugh, JJ
    Hollender, ES
    Jones, D
    Pitchenik, AE
    Ashkin, D
    [J]. CLINICAL INFECTIOUS DISEASES, 2000, 30 (05) : 779 - 783